KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) EBIAT (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBIAT for 16 consecutive years, with -$141.6 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 203.34% to -$141.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $316.9 million through Dec 2025, down 28.64% year-over-year, with the annual reading at $316.9 million for FY2025, 28.64% down from the prior year.
  • EBIAT for Q4 2025 was -$141.6 million at Halozyme Therapeutics, down from $175.2 million in the prior quarter.
  • The five-year high for EBIAT was $216.6 million in Q3 2021, with the low at -$141.6 million in Q4 2025.
  • Average EBIAT over 5 years is $82.4 million, with a median of $79.3 million recorded in 2023.
  • The sharpest move saw EBIAT soared 557.07% in 2021, then plummeted 203.34% in 2025.
  • Over 5 years, EBIAT stood at $66.8 million in 2021, then fell by 13.58% to $57.7 million in 2022, then skyrocketed by 47.98% to $85.4 million in 2023, then skyrocketed by 60.46% to $137.0 million in 2024, then tumbled by 203.34% to -$141.6 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$141.6 million, $175.2 million, and $165.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.